reduce basal insulin when starting glp-1 receptor agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]

[DOI] [PubMed] [Google Scholar] 664.Skov J., Holst J.J., Gotze J.P., Frokiaer J., Christiansen J.S

Disruption in iron homeostasis, including increased transferrin receptor expression and ferritin degradation via NCOA4-mediated ferritinophagy, contributes to ferroptotic susceptibility ( Lipid Peroxidation: Polyunsaturated fatty acids (PUFAs), especially arachidonic and adrenic acids, are substrates for lipoxygenases (LOX), which drive peroxidation in membrane phospholipids, generating cytotoxic lipid peroxides such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) ( Glutathione Depletion and GPX4 Inactivation: System Xc imports cystine for GSH synthesis

However, a standard dose is two pills per day, so each bottle only contains a 15- or 45-day supply, respectively

No hype, just trade-offs

(Curr Pharm Des, 2018) tracked adverse events in 200 patients using various BPC-157 formulations over 12 weeks